MUTATIONS OF THE PIK3CA GENE IN HUMAN CANCERS
    4.
    发明公开
    MUTATIONS OF THE PIK3CA GENE IN HUMAN CANCERS 审中-公开
    PIK3CA基因在人类癌症中的突变

    公开(公告)号:EP3296407A1

    公开(公告)日:2018-03-21

    申请号:EP17197306.8

    申请日:2005-02-18

    IPC分类号: C12Q1/68

    CPC分类号: C12Q1/6886 C12Q2600/156

    摘要: Phosphatidylinositol 3-kinases (PI3Ks) are known to be important regulators of signaling pathways. To determine whether PI3Ks are genetically altered in cancers, we analyzed the sequences of the P13K gene family and discovered that one family member, PIK3CA, is frequently mutated in cancers of the colon and other organs. The majority of mutations clustered near two positions within the P13K helical or kinase domains. PIK3CA represents one of the most highly mutated oncogenes yet identified in human cancers and is useful as a diagnostic and therapeutic target.

    摘要翻译: 已知磷脂酰肌醇3-激酶(PI3K)是信号传导途径的重要调节剂。 为了确定PI3K是否在癌症中被遗传改变,我们分析了P13K基因家族的序列并发现一个家族成员PIK3CA在结肠和其他器官的癌症中经常发生突变。 大部分突变聚集在P13K螺旋或激酶结构域内的两个位置附近。 PIK3CA代表人类癌症中鉴定的突变最严重的癌基因之一,并且可用作诊断和治疗靶标。

    SAFE SEQUENCING SYSTEM
    7.
    发明公开

    公开(公告)号:EP3907299A1

    公开(公告)日:2021-11-10

    申请号:EP21173115.3

    申请日:2012-04-12

    摘要: The identification of mutations that are present in a small fraction of DNA templates is essential for progress in several areas of biomedical research. Though massively parallel sequencing instruments are in principle well-suited to this task, the error rates in such instruments are generally too high to allow confident identification of rare variants. We here describe an approach that can substantially increase the sensitivity of massively parallel sequencing instruments for this purpose. One example of this approach, called "Safe-SeqS" for (Safe-Sequencing System) includes (i) assignment of a unique identifier (UID) to each template molecule; (ii) amplification of each uniquely tagged template molecule to create UID-families; and (iii) redundant sequencing of the amplification products. PCR fragments with the same UID are truly mutant ("super-mutants") if =95% of them contain the identical mutation. We illustrate the utility of this approach for determining the fidelity of a polymerase, the accuracy of oligonucleotides synthesized in vitro, and the prevalence of mutations in the nuclear and mitochondrial genomes of normal cells.